CN101766818B - 多糖金磁复合微粒载药体及其制备方法 - Google Patents
多糖金磁复合微粒载药体及其制备方法 Download PDFInfo
- Publication number
- CN101766818B CN101766818B CN2008102365404A CN200810236540A CN101766818B CN 101766818 B CN101766818 B CN 101766818B CN 2008102365404 A CN2008102365404 A CN 2008102365404A CN 200810236540 A CN200810236540 A CN 200810236540A CN 101766818 B CN101766818 B CN 101766818B
- Authority
- CN
- China
- Prior art keywords
- gold
- magnetic
- polysaccharide
- composite particle
- magnetic composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 113
- 239000011246 composite particle Substances 0.000 title claims abstract description 97
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 96
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 96
- 150000004676 glycans Chemical class 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 229920001503 Glucan Polymers 0.000 claims abstract description 36
- 239000006249 magnetic particle Substances 0.000 claims abstract description 32
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000006185 dispersion Substances 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims description 43
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 26
- 229930195573 Amycin Natural products 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 26
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 26
- 239000012498 ultrapure water Substances 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 230000009514 concussion Effects 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 15
- 239000005030 aluminium foil Substances 0.000 claims description 12
- 238000007885 magnetic separation Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 6
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims description 5
- 208000035126 Facies Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 14
- 238000011068 loading method Methods 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 3
- 230000003578 releasing effect Effects 0.000 abstract 2
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 38
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 19
- 239000010931 gold Substances 0.000 description 19
- 229910052737 gold Inorganic materials 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 239000004531 microgranule Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 4
- LJZPVWKMAYDYAS-UHFFFAOYSA-N Aklavine Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC1CC(N(C)C)C(O)C(C)O1 LJZPVWKMAYDYAS-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 4
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 4
- LJZPVWKMAYDYAS-QKKPTTNWSA-N aclacinomycin T Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 LJZPVWKMAYDYAS-QKKPTTNWSA-N 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 190000008236 carboplatin Chemical compound 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 4
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 229950008991 lobaplatin Drugs 0.000 description 4
- 239000002122 magnetic nanoparticle Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229940023146 nucleic acid vaccine Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004567 concrete Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- -1 amido modified Superparamagnetic Iron Oxide Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000011553 magnetic fluid Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical group O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- RIVZIMVWRDTIOQ-UHFFFAOYSA-N cobalt iron Chemical compound [Fe].[Co].[Co].[Co] RIVZIMVWRDTIOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/01—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials
- H01F1/03—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity
- H01F1/032—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials
- H01F1/04—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys
- H01F1/06—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder
- H01F1/061—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder with a protective layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Power Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102365404A CN101766818B (zh) | 2008-12-30 | 2008-12-30 | 多糖金磁复合微粒载药体及其制备方法 |
US13/142,820 US20120121717A1 (en) | 2008-12-30 | 2008-12-30 | DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD |
PCT/CN2008/002130 WO2010078675A1 (zh) | 2008-12-30 | 2008-12-30 | 多糖金磁复合微粒载药体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102365404A CN101766818B (zh) | 2008-12-30 | 2008-12-30 | 多糖金磁复合微粒载药体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101766818A CN101766818A (zh) | 2010-07-07 |
CN101766818B true CN101766818B (zh) | 2013-05-22 |
Family
ID=42316175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102365404A Active CN101766818B (zh) | 2008-12-30 | 2008-12-30 | 多糖金磁复合微粒载药体及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120121717A1 (zh) |
CN (1) | CN101766818B (zh) |
WO (1) | WO2010078675A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075639A1 (zh) | 2008-12-31 | 2010-07-08 | 陕西北美基因股份有限公司 | 四氧化三铁磁性纳米微球的制备方法 |
HUE050303T2 (hu) * | 2013-03-13 | 2020-11-30 | Intervet Int Bv | Stabil bioaktív szubsztanciák és eljárások elõállítására |
CN113061575B (zh) * | 2021-03-25 | 2023-04-07 | 中国人民解放军陆军军医大学 | 从大龄小鼠结肠固有层中分离纯化固有淋巴样细胞的方法 |
CN113287569B (zh) * | 2021-05-27 | 2023-04-07 | 四川康城生物科技有限公司 | 一种免疫低下动物模型的构建方法 |
CN116589019B (zh) * | 2023-05-26 | 2023-10-27 | 深圳市一号芯环保科技有限公司 | 一种长效缓释型杀菌及抗氧化功能滤芯材料及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041095A1 (en) * | 2001-11-05 | 2003-05-15 | Universidade Federal De Minas Gerais - Ufmg | Process of composites preparation between particulate materials and cyclodextrins and/or their derivatives products thereof |
CN1542449A (zh) * | 2003-04-30 | 2004-11-03 | �����ɷ� | 一种核/壳型超顺磁性复合微粒及其制备方法与应用 |
CN1580765A (zh) * | 2003-08-14 | 2005-02-16 | 陕西西大北美基因股份有限公司 | 一种组装型磁性复合微粒及其制备方法与应用 |
GB2415374A (en) * | 2004-06-25 | 2005-12-28 | Leuven K U Res & Dev | Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles |
CN101164621A (zh) * | 2006-10-19 | 2008-04-23 | 陕西西大北美基因股份有限公司 | 超顺磁性复合微粒载药体及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033938A1 (en) * | 2000-09-12 | 2004-02-19 | Britten Nancy J. | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
AU2003215388A1 (en) * | 2002-02-22 | 2003-09-09 | Purdue Research Foundation | Magnetic nanomaterials and methods for detection of biological materials |
US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
CN1476896A (zh) * | 2002-08-23 | 2004-02-25 | 张阳德 | 纳米药物载体的制法 |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
GB0313259D0 (en) * | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
US7452554B2 (en) * | 2003-09-03 | 2008-11-18 | Apt Co, Ltd. | Platinum nanocolloid solution, process for producing the same and drink containing platinum nanocolloid |
JP2008515915A (ja) * | 2004-10-07 | 2008-05-15 | エモリー ユニバーシティー | 多機能性ナノ粒子結合体およびそれらの使用 |
JP2007210966A (ja) * | 2006-02-10 | 2007-08-23 | Hitachi Maxell Ltd | 生体物質で被覆された磁性体の製造方法 |
EP1952919B1 (en) * | 2007-02-02 | 2013-04-24 | FUJIFILM Corporation | Magnetic nanoparticles and aqueous colloid composition containing the same |
CN100415808C (zh) * | 2007-02-08 | 2008-09-03 | 上海交通大学 | 水溶性多糖基磁性复合纳米粒子的制备方法 |
-
2008
- 2008-12-30 WO PCT/CN2008/002130 patent/WO2010078675A1/zh active Application Filing
- 2008-12-30 CN CN2008102365404A patent/CN101766818B/zh active Active
- 2008-12-30 US US13/142,820 patent/US20120121717A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041095A1 (en) * | 2001-11-05 | 2003-05-15 | Universidade Federal De Minas Gerais - Ufmg | Process of composites preparation between particulate materials and cyclodextrins and/or their derivatives products thereof |
CN1542449A (zh) * | 2003-04-30 | 2004-11-03 | �����ɷ� | 一种核/壳型超顺磁性复合微粒及其制备方法与应用 |
CN1580765A (zh) * | 2003-08-14 | 2005-02-16 | 陕西西大北美基因股份有限公司 | 一种组装型磁性复合微粒及其制备方法与应用 |
GB2415374A (en) * | 2004-06-25 | 2005-12-28 | Leuven K U Res & Dev | Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles |
CN101164621A (zh) * | 2006-10-19 | 2008-04-23 | 陕西西大北美基因股份有限公司 | 超顺磁性复合微粒载药体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20120121717A1 (en) | 2012-05-17 |
WO2010078675A1 (zh) | 2010-07-15 |
CN101766818A (zh) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Nanoparticles modified by polydopamine: Working as “drug” carriers | |
Baeza et al. | Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks | |
Cheng et al. | pH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy | |
Huang et al. | New advances in gated materials of mesoporous silica for drug controlled release | |
CN103028116B (zh) | 基于纤维素基模板的磁性纳米复合微球及其制法和用途 | |
Zhao et al. | Spatiotemporally light-activatable platinum nanocomplexes for selective and cooperative cancer therapy | |
CN101766818B (zh) | 多糖金磁复合微粒载药体及其制备方法 | |
Chen et al. | Recent developments of mesoporous silica nanoparticles in biomedicine | |
WO2013075394A1 (zh) | 具有螯合型复合微胞的药物载体及其应用 | |
CN105833272A (zh) | 一种多功能纳米药物组合物及其制备方法与应用 | |
CN104840977A (zh) | 一种磁性荧光复合纳米药物载体的制备方法 | |
You et al. | Dendritic mesoporous organosilica nanoparticles: a pH-triggered autocatalytic fenton reaction system with self-supplied H2O2 for generation of high levels of reactive oxygen species | |
Zhuang et al. | Mesoporous silica nanoparticles as carrier to overcome bacterial drug resistant barriers | |
Kumar et al. | Recent progresses in Organic-Inorganic Nano technological platforms for cancer therapeutics | |
Hamza et al. | An approach for magnetic halloysite nanocomposite with selective loading of superparamagnetic magnetite nanoparticles in the lumen | |
Ali et al. | Biodegradable magnetic molecularly imprinted anticancer drug carrier for the targeted delivery of docetaxel | |
Rajan et al. | Polymeric nanoparticles in hybrid catalytic processing and drug delivery system | |
WO2019006881A1 (zh) | 一种接枝改性黄原胶纳米微凝胶的制备方法 | |
TWI791640B (zh) | 奈米載體、其製備方法、其用途及包括其的可注射的醫藥溶液 | |
Akl et al. | Biodegradable functionalized magnetite nanoparticles as binary-targeting carrier for breast carcinoma | |
Wu et al. | Preparation and characterization of magnetic ferrite-chitosan nanoparticles delivery for DOX | |
CN104490791B (zh) | 一种磁性超支化聚酯复合载药微球及其制备方法 | |
Khan et al. | Nano‐therapeutics: The upcoming nanomedicine to treat cancer | |
CN100502881C (zh) | 可降解聚合物载柔红霉素纳米微球及其制备方法 | |
CN114404604B (zh) | 一种碘驱动靶向识别智能响应型磁性纳米递药系统及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: XI AN GOLDMAG NANOBIOTECH CO., LTD. Free format text: FORMER OWNER: SHAANXI BAIMEI GENE CO., LTD. Effective date: 20130719 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHAANXI BAIMEI GENE CO., LTD. Free format text: FORMER NAME: SHAANXI LIFEGEN CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710069 XI AN, SHAANXI PROVINCE TO: 710077 XI AN, SHAANXI PROVINCE |
|
CP01 | Change in the name or title of a patent holder |
Address after: 710069 No. 386, 229 Taibai Road, Shaanxi, Xi'an, China Patentee after: SHAANXI LIFEGEN Co.,Ltd. Address before: 710069 No. 386, 229 Taibai Road, Shaanxi, Xi'an, China Patentee before: Shaanxi North American Gene Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130719 Address after: 710077, Shaanxi, Xi'an hi tech Zone, No. 85, No. 4, No. 2, modern enterprise center, 3 east side, 10402A Patentee after: XI'AN GOLDMAG NANOBIOTECH Co.,Ltd. Address before: 710069 No. 386, 229 Taibai Road, Shaanxi, Xi'an, China Patentee before: SHAANXI LIFEGEN Co.,Ltd. |